Genflow Appoints US Biotech Veteran to Lead Strategic Longevity Push
Gosselies, Monday 19 January 2026 Genflow appoints Gad Berdugo as Chairman to leverage his 30-year US biotech track record, aiming to accelerate its RNA-based longevity therapies and expand its global market presence.
Strategic Leadership Update
Genflow Biosciences (LSE: GENF) has officially appointed Gad Berdugo as its new Independent Non-Executive Chairman, a move announced on Monday, 19 January 2026 [2][3]. This appointment marks a pivotal shift for the London-based biotechnology firm, which maintains its research and development facilities in Belgium [3]. The decision to bring Berdugo on board is explicitly linked to the company’s objective of expanding its presence in the United States and accelerating its gene therapy programmes [4]. Dr Eric Leire, Chief Executive Officer of Genflow, noted that Berdugo’s arrival comes as the company seeks to leverage specific expertise in strategy, partnerships, and financing to expand its global reach [2][3].
Strengthening US Governance
Berdugo brings over 30 years of leadership experience to the role, with a particular focus on the US capital markets and global business development [4]. Currently serving as the Managing Partner of Explorium Capital LLC, a US-based advisory firm for the biotech sector, his background aligns closely with Genflow’s technical requirements [3][4]. His previous tenure includes serving as Chief Business Officer at Editas Medicine (NASDAQ: EDIT) and Nutcracker Therapeutics, as well as holding the position of CEO at EpiVax Oncology [2][3]. Crucially for Genflow’s scientific direction, Berdugo possesses deep technical expertise in RNA-based therapeutics and lipid nanoparticle (LNP) delivery systems [4]. As part of this governance restructure, the outgoing Chair, Tamara Joseph, will retain a seat on the board as a Non-Executive Director to ensure continuity [1][4].
From R&D to Clinical Data
The leadership change occurs as Genflow navigates a critical period of clinical validation. The company is currently midway through a 12-month proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs, a study that commenced in March 2025 [3]. In addition to the ongoing veterinary trial, Genflow is planning a clinical trial to investigate the efficacy of its GF-1002 compound in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) [3]. Berdugo has indicated that the company is entering a new phase of development, with key data readouts from these initiatives expected later in 2026 [2]. This sharpened focus on high-potential programmes and strengthened intellectual property underscores the company’s transition from early-stage research toward clinical maturity [2].